GV20 Oncotherapy focuses on the selection of effective targets for cancer drugs and developing new approaches to personalized cancer diagnosis and therapy. We have advanced technologies, world-class team and strong financial support.
In GV20 Oncotherapy，We have first-class research resources. We aim to promote accurate medical development and provide accurate and reliable information for cancer treatment and therapeutic products.
Our core members are from the prestigious universities in China or the U.S. and we have a good mastery of next-generation sequencing technology, CRISPR screening experiments and data analysis. We have published several related works in the top scientific research magazines.
We focus on gene selection based on CRISPR technologies, including cancer essential genes, synthetic lethal genes, and genes related to drug reaction and drug-resistant.